Twitter Facebook Linked In Zone In Google Plus 
September 2018 Research Update

Is DNA Synthesis Going Enzymatic?

Earlier this summer, researchers from Jay Keasling's lab at the Department of Energy's Joint BioEnergy Institute (JBEI), based at Lawrence Berkeley National Laboratory, published a novel method to synthesize oligonucleotides in Nature Methods. Specifically, they revealed an enzymatic approach to oligonucleotide synthesis that offers several key advantages over traditional oligonucleotide synthesis, including increased specificity, increased oligonucleotide length, and a more environmentally friendly process.

Throughout the years, oligonucleotide synthesis has gone through several methods and iterations, beginning with the H-phosphonate method developed by Alexander Todd's group in the 1950s, and continuing with the nucleoside phosphoramidite method developed by M. Caruthers' group in the 1970s, which is still predominantly used today (see Hogrefe et al. 2013 for a review of the history and challenges of oligonucleotide synthesis).

"However, after decades of fine-tuning and improvements in liquid handling, the upper limit of phosphoramidite-based oligo synthesis is now about 200-300 nt, in practice. As a result, longer molecules must be assembled from oligos in a process that is failure-prone and not amenable to all target sequences, rendering some DNA sequences inaccessible to study," noted the authors...

Read More
 
Come and See Us
Oligo Therapeutics
Society (OTS)

Sept 30 - Oct 3, 2018
Seattle, WA
American Society of Human Genetics (ASHG)
Booth # 1017
Oct 16-20, 2018
San Diego, CA
Why Limit Your Success with Standard Two-part RNA Guides
Our custom synthetic high-performance single guide RNA (sgRNA) with sequence specific backbone and base modifications ensure the most effective binding and knock-out/knock-in efficiency for all your CRISPR Cas9 experiments.
OligoBuilder
Get instant pricing & ordering for modified and standard oligos from 0.2 µmole to 15 µmole synthesis scales.
Regulation of mRNA Fate and Function by Epitranscriptomic Nucleotide Modifications

Join Us

For a free live educational webcast uncovering insights into: Regulation of mRNA Fate and Function by Epitranscriptomic Nucleotide Modifications featuring Sammie Jaffrey M.D., Ph.D. and Anton McCaffrey Ph.D.

Register now to access the live expert-led presentation with Q&A, download exclusive whitepapers and videos, or to access the post-event recording.

September 19, 2018 11am EDT

register now

 
CRISPR
 
Ask An Expert

We need to quickly move forward with our novel therapeutic oligo. Can TriLink produce clinical grade material and quantities?

Yes! For over 20 years, we've been industry leaders synthesizing high quality research and diagnostic grade material, especially difficult and unusual constructs. We combine our expertise with a state-of-the art GMP manufacturing facility to offer mRNA, oligonucleotide and small molecule therapeutic development and...

Read More
Zone In With The Zon Blog Post

Deluge of mRNA Delivery Publications

Devotees of this blog may recall my past post in 2013 titled Modified mRNA Mania, which intentionally used the word "mania" to provoke reading about the trending topic on base-modified mRNA as therapeutic agents. My metrics for this mania were a flurry of of scientific publications, patent applications staking out...

View Blog Post


 

 
 
© 2018 TriLink BioTechnologies | All Rights Reserved